Genprex Inc - GNPX STOCK NEWS

Genprex announced that its research collaborators will present positive preclinical data for their diabetes gene therapy drug candidate GPX-002 at the ASGCT 28th Annual Meeting in New Orleans this May.

The research focuses on a novel gene therapy using recombinant adeno-associated virus (rAAV) to treat diabetes mellitus. Key findings show that retrograde intraductal infusion of rAAV6 successfully delivered Pdx1 and MafA genes, converting alpha cells into insulin-secreting beta-like cells.

Testing on non-human primates demonstrated:

• Improved glucose tolerance and reduced insulin needs one month post-infusion
• Durable effects using AAV6 capsid with endocrine-specific promoters
• Successful immune response management using temporary immunosuppression
• Sustained therapeutic effects even after stopping immunosuppression

The research represents a potential breakthrough in diabetes treatment, with results showing sustained therapeutic effects without long-term immunosuppression requirements.

Genprex (NASDAQ: GNPX) has signed an exclusive patent license agreement with NYU Langone Health for Reqorsa® Gene Therapy to treat mesothelioma. The therapy shows promising preclinical results in treating Malignant Pleural Mesothelioma (MPM).

Research data presented at the 2024 EORTC-NCI-AACR Symposium demonstrated that REQORSA significantly decreased cell proliferation and invasion while increasing cell apoptosis in MPM cell lines. The therapy utilizes the TUSC2 tumor suppressor gene, which is downregulated in 84% of mesotheliomas.

Genprex formed a Mesothelioma Clinical Advisory Board in 2024 with four leading researchers to support its preclinical program. According to CDC data, mesothelioma affects approximately 3,000 new cases annually in the U.S., with a life expectancy of 18 months and a 3-year survival rate of 23% with treatment.

Genprex (NASDAQ: GNPX) has been selected to present at the 2025 ASCO Annual Meeting in Chicago, showcasing their Acclaim-3 Phase 1/2 clinical trial design. The presentation will focus on Reqorsa® Gene Therapy (quaratusugene ozeplasmid) in combination with Tecentriq® as maintenance therapy for extensive stage small cell lung cancer (ES-SCLC).

The presentation is scheduled for May 31, 2025, from 1:30 to 4:30 p.m. CT, and will be delivered by Dr. Bo Wang from Oncology Associates of Oregon. The abstract will be featured in the Trials in Progress poster session, highlighting the company's innovative approach in cancer treatment development.

Genprex (NASDAQ: GNPX) announced the publication of their research collaborators' abstract in Cancer Research's online Proceedings supplement. The abstract, which will be presented at the 2025 AACR Annual Meeting, showcases positive preclinical data for Reqorsa® Gene Therapy in treating KRASG12C mutant non-small cell lung cancer (NSCLC).

The research demonstrates that TUSC2 gene therapy (REQORSA) effectively overcomes sotorasib acquired resistance in KRASG12C mutant NSCLC mouse xenografts. Key findings show that TUSC2 transfection reduced colony formation in resistant cell lines, increased apoptosis, and decreased organoid viability. The treatment showed significant antitumor efficacy, particularly when combined with sotorasib in resistant tumors.

Genprex announced that its research collaborators will present positive preclinical data for Reqorsa® Gene Therapy at the 2025 AACR Annual Meeting in Chicago. The study focuses on treating KRASG12C mutant non-small cell lung cancer (NSCLC), particularly addressing resistance to Lumakras® (sotorasib).

The preclinical data demonstrated that TUSC2 gene therapy (REQORSA) effectively overcomes sotorasib acquired resistance in KRASG12C mutant NSCLC mouse xenografts. Key findings show that TUSC2 transfection reduced colony formation in resistant cell lines, increased apoptosis, and decreased organoid viability. The treatment showed significant antitumor efficacy both as a standalone therapy and in combination with sotorasib in resistant tumors.

Genprex (NASDAQ: GNPX) announced that its research collaborators will present positive preclinical data for GPX-002, their diabetes gene therapy drug candidate, at the 2025 American Diabetes Association 85th Scientific Sessions in Chicago.

GPX-002 is being developed as a potential disease-modifying therapy for both Type 1 and Type 2 diabetes, aiming to eliminate the need for daily blood glucose monitoring and insulin replacement therapy. Recent company developments include:

• Signing an amended license agreement for multiple diabetes gene therapy technologies
• Formation of Convergen Biotech subsidiary focused on diabetes program development
• Addition of research on re-dosable non-viral delivery systems

Two presentations are scheduled: a poster presentation on lipid nanoparticles for islet cell transfection, and an oral presentation on AAV-mediated gene therapy treatment in non-human primates with streptozotocin-induced diabetes.

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company, has announced its participation in BIO Europe Spring 2025, scheduled for March 17-19 in Milan, Italy. Ryan Confer, President and CEO, and Thomas Gallagher, Senior VP of Intellectual Property and Licensing, will represent the company.

The executives will be available for one-on-one meetings with industry groups to discuss Genprex's gene therapies for cancer and diabetes. The conference is expected to attract over 3,700 executives from biotech, pharma, and finance sectors, facilitating more than 20,000 one-on-one meetings.

Interested parties can schedule meetings through the conference portal or by contacting Genprex's Investor Relations at investors@genprex.com.

Genprex (NASDAQ: GNPX) announced advancement in its diabetes program through a strategic collaboration with a CDMO partner to research a non-viral lipid nanoparticle delivery system for its diabetes gene therapy drug candidate. This alternative approach represents a second-generation development, separate from existing preclinical programs.

The company's current diabetes treatment, GPX-002, uses an AAV vector containing Pdx1 and MafA genes administered into the pancreatic duct. While effective, viral delivery systems cannot be readministered due to immune responses. The non-viral approach could enable multiple treatments, potentially optimizing patient outcomes.

Recent preclinical studies showed GPX-002's effectiveness in Type 1 NOD mouse models, maintaining glucose control for approximately 120 days, significantly longer than the 17-day median observed with traditional islet cell transplants. The therapy is being developed for both Type 1 and Type 2 diabetes, working by transforming pancreatic alpha cells into functional beta-like cells.

Genprex (NASDAQ: GNPX) has announced significant developments in its diabetes gene therapy program. The company has signed an amended exclusive license agreement with the University of Pittsburgh, consolidating multiple technologies for Type 1 and Type 2 diabetes gene therapy. The agreement covers worldwide exclusive rights to patent applications and technologies related to gene therapy using Pdx1 and MafA transcription factors.

The company has also formed Convergen Biotech, a wholly-owned subsidiary focused on diabetes program development. Their gene therapy product, GPX-002, is designed to transform pancreatic alpha cells into functional beta-like cells for T1D treatment and rejuvenate exhausted beta cells for T2D treatment. The therapy is administered via routine endoscopy into the pancreatic duct.

Genprex plans to seek FDA guidance for preclinical studies needed for IND application by the second half of 2025. The separation of the diabetes program into Convergen Biotech aims to expedite clinical development and enable potential direct investment and strategic collaboration.